Business Context and Reporting Period
This Form 8-K Current Report was filed by Relay Therapeutics, Inc. on October 7, 2021, with the earliest event reported on October 7, 2021. The filing serves as a Regulation FD disclosure and report of other events, focusing on the announcement of preclinical data for RLY-2608 and interim clinical data for RLY-4008 presented at the AACR-NCI-EORTC Molecular Targets Conference.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding clinical and preclinical progress rather than a financial statement.
Material Changes and Clinical Updates
RLY-2608 (Preclinical Data)
- Target: Mutant-selective inhibitor of PI3Kα (variants H1047X, E542X, E545X).
- Mechanism: Binds to a novel allosteric site discovered via the Dynamo platform, sparing wild-type PI3Kα.
- Efficacy: Achieved tumor regression in in vivo xenograft models with significantly reduced impact on glucose metabolism compared to non-mutant selective inhibitors.
- Market Potential: Could address over 100,000 patients per year in the U.S.
- Timeline: First-in-human clinical trial expected to initiate in the first half of 2022, subject to FDA acceptance of the IND.
RLY-4008 (Interim Clinical Data)
- Target: FGFR2 inhibitor for patients with FGFR2-altered tumors.
- Trial Status: RLY-4008-101 Trial (dose-escalation first-in-human); 49 subjects treated as of the September 9, 2021 data cut-off.
- Safety: Generally well tolerated. No Grade 4 or 5 adverse events. Once-daily (QD) dosing prioritized due to preferable tolerability (only one DLT observed) and high target coverage (>85% receptor occupancy at 20 mg).
- Off-Target Toxicity: Minimal hyperphosphatemia (16% of patients, all Grade 1-2) and little to no diarrhea, suggesting high selectivity against FGFR1 and FGFR4.
- Efficacy: Approximately 80% of all patients achieved radiographic tumor regressions.
- Key Subgroups:
- Cholangiocarcinoma (Naïve): 100% tumor shrinkage in 6 pan-FGFR treatment-naïve patients; 3 confirmed partial responses (-56% to -83% regression).
- Resistance Mutations: Radiographic tumor shrinkage and complete clearance of ctDNA in 70% of patients with acquired resistance mutations.
- Timeline: Company plans to select a recommended Phase 2 dose and initiate expansion cohorts prior to the end of 2021.
Guidance, Outlook, and Risks
Management intends to host a conference call on October 8, 2021, to discuss these data points. The filing includes standard forward-looking statements regarding the timing of clinical trials, potential therapeutic effects, and regulatory interactions. Key risks identified include the impact of COVID-19, delays in clinical trials, the unpredictability of clinical results, and the ability to demonstrate safety and efficacy. The company explicitly disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the submission and acceptance of the Investigational New Drug (IND) application for RLY-2608 to confirm the H1 2022 trial start date.
- Monitor the selection of the recommended Phase 2 dose for RLY-4008 and the initiation of expansion cohorts before year-end 2021.
- Review the full clinical data presentation (Exhibit 99.3) for detailed safety profiles, specifically regarding retinal toxicity (observed in 14% of patients, all Grade 1-2).
- Assess the durability of tumor responses in patients with acquired resistance mutations to validate the potential for treating on-target resistance.
- Confirm the company's cash runway and capital requirements, as this filing does not disclose financial liquidity.